Key statistics dashboard for AIM ImmunoTech Inc. (AIM). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States.
Stock Data
| Price | $0.21 |
| Market Cap | $1M |
| Enterprise Value | -$5.3M |
| Beta | 1.36 |
| Exchange | AMEX |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.06 |
| Price / Book | 0.47 |
| P/S | 7.65 |
| EV/EBITDA | 0.41 |
| EV/Sales | -55.34 |
| EV/FCF | 0.73 |
| P/FCF | -0.10 |
| Earnings Yield | -393.20% |
| FCF Yield | -992.31% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -125.26% |
| EBIT Margin | -13823.16% |
| EBITDA Margin | -13629.47% |
| Operating Margin | -11637.89% |
| Net Margin | -15021.05% |
| Return on Equity | 952.76% |
| Return on Assets | -112.09% |
| Return on Invested Capital | -94.78% |
| Return on Capital Employed | -142.02% |
Financial Health
| Current Ratio | 2.11 |
| Quick Ratio | 2.11 |
| Cash Ratio | 2.00 |
| Debt / Equity | 0.51 |
| Debt / Assets | 30.80% |
| Net Debt / EBITDA | 0.46 |
| Interest Coverage | -9.72 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | 0.45 |
| Cash per share | 0.58 |
| FCF per share | -0.42 |
| Tangible Book Value per share | 0.35 |
| Dividend per share | 0.00 |
Related companies: CANF · ENSC · KALA · KTTA · OGEN · QNRX · SNGX
Explore sector: Healthcare · Biotechnology
More sections of AIM: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks